Pay in 4 interest-free payments of $5.47 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Jakafi (ruxolitinib) Indication(s): Intermediate or highrisk myelofibrosis, polycythemia vera (after hydroxyurea failure), acute graftversushost disease (GVHD) and chronic GVHD in adults (and pediatric patients 12 years and older) Manufacturer(s): Incyte (in the US)/Novartis 2024 Sales: $4.73 billion Why it sold so well: Jakafi generated approximately $2.8 billion in sales in 2024, marking a solid 8% YoY increase
8 This suggests that GLP-1RAs can be beneficial in stabilising high-risk HFpEF patients and reducing subsequent exacerbations
Researchers dealing with autoimmune-related tissue damage, chronic inflammatory conditions, or gut-related repair often prefer this expanded stack
doi: 10.1073/pnas.1219451110 72 WangLLiPTangZYanXFengB
US$ 25.83
US$ 24.25
US$ 28.72
US$ 20.67
US$ 28.51
